Manufacturers

Work worth doing: Innovative field solutions

Manufacturers

Essential skills for outsourced field solutions teams

Manufacturers

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

HTA Quarterly | Fall 2023

Manufacturers

Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

Optimize your pre-approval information exchange strategy

Manufacturers

How to forge stronger working relationships with payers

Manufacturers

The essential guide to drug commercialization

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

Manufacturers

Three questions to ask about your market access partner

Manufacturers

Acceleration of innovation in healthcare delivery

Manufacturers

HTA Quarterly | Summer 2023

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

HTA Quarterly | Winter 2022

Closing the Gaps in Pre-Approval Information Exchange to Accelerate Product Success and Patient Access

Manufacturers

HTA Quarterly | Fall 2022

Upcoming cost-containing measures in Germany—How will they affect the biopharmaceutical industry?

Manufacturers

Market access abroad: Three reasons why early planning is critical for HTA countries

Manufacturers

Innovative agreements: Exploring alternative payment models

Manufacturers

Why FormularyDecisions® is the right choice for enterprise biopharma payer engagement 

Alopecia areata: A global perspective of a disease that extends beyond hair loss

Manufacturers

Webinar slides: Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies

Research poster: The current impact of ICER assessments on payer decision making

Orphan drugs: trapped in the lock? A review of the lock system in the Netherlands

Medicaid Best Price and Its Implications on Cell and Gene Therapy Products

Manufacturers

Differentiate your product with FormularyDecisions®

Manufacturers

Six insights driving the evolution of FormularyDecisions®

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

The drug reimbursement environment in Canada: An overview

HTA Quarterly | Spring 2022

Joint clinical assessment in the EU: Pan-European HTA for drugs and medical devices will become reality 

The UK Innovative Licensing and Access Pathway—A new paradigm in market access

HTA Quarterly | Winter 2021

Is NICE becoming nicer?

Evidence generation and approval of digital health applications in Germany

Manufacturers

Building your field reimbursement and access team: The translational experience and skills that matter most

Health disparities and health technology assessment: Current value assessment frameworks fall short

HTA Quarterly | Fall 2021

Elucidating ICER’s methodologies for Unsupported Price Increase assessments  

Equity considerations in US value assessment: Opportunities ahead

Manufacturers

Navigating the payer landscape for digital therapeutics

Manufacturers

Work worth doing: FormularyDecisions

HTA Quarterly | Summer 2021

Manufacturers

Ebook: Strategic partnerships for unlocking product potential

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

Manufacturers

Webinar: uptake or heartbreak with biosimilars? Progress and perspectives

Manufacturers

Checklist: Four things to look for in a field services partner

The impact of obesity on COVID-19 outcomes of hospitalizations and mortality

Patient forward: comparing ICER and PCORI use of patient feedback

Manufacturers

Case study: an innovative field reimbursement program expands patient access

Manufacturers

Pharma in the field: Ashley's story

Manufacturers

Pharma in the field: Tierra's story

HTA Quarterly | Winter 2020

Ushering in a New Era of Antibiotic Innovation With a Netflix-Style Subscription Payment Model

HTA and Affordability for Innovative Therapies in Germany, Perspectives on Advanced Therapy Medicinal Product (ATMP) Pathway

Manufacturers

Ebook: Virtual drug commercialization

AMCP Nexus 2020 Virtual Recap

Manufacturers

Is a contact-free clinical trial possible?

Manufacturers

Is your PIE incomplete?

Webinar: 5 Years of ICER - Insights and Impact on Payers

Case study: Gaining payer attention through digital innovation

Manufacturers

Rethink field services: Three myths keeping access barriers in front of your product

Manufacturers

Solving access, reimbursement, and PAP awareness problems

Feature Article: 20 Years After the National Health Insurance Act, HTA Policy Changes Reshape Market Access in South Korea

Market Trends and Updates: New Pharmaceutical Policies Have Dramatically Changed the Landscape in China

Therapeutic Spotlight: New Evidence Brings Cautious Optimism to Alzheimer’s Disease Treatment

Webinar | Navigating COVID-19: Simplifying the Path to Better Patient Outcomes

HTA Quarterly | Fall 2020

Manufacturers

Pharma in the field: Sales reps vs. reimbursement and access specialists

Manufacturers

The Future of Payer Engagement: How Pharma Can Break Through

Manufacturers

The Value of Virtual: How Remote Workshops Can Keep Market Access Efforts Moving

HTA Quarterly | Summer 2020

Regulatory and Market Access Impact in Europe of the Recent Medical Software Makers Guidance

Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball

The Era of mHealth: A Global Perspective

Manufacturers

Distant But Engaged: Transitioning to Virtual Training

Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies

Manufacturers

Mind the (Evidence) Gap

HTA Quarterly | Fall 2019

Manufacturers

Biosimilars: Launch Insights From the Field

HTA Quarterly | Summer 2019

Review of HTA Frameworks and Decisions for Next-Generation Sequencing in Precision Oncology

Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?

Rise of Complex Technologies and a Challenging Reimbursement Landscape: How a Forward-Looking Indirect Treatment Comparison Feasibility Study Can Help Navigate Market Access

Healthcare System Changes in France

Manufacturers

How Digital Innovation Drives Improved Market Access Strategies

Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions

HTA Quarterly | Spring 2019

Diabetes and the Growing Investment in Drugs, Devices, and Diagnostics 

MCDA: Too Much Talk, Too Little Progress?

HTA Quarterly | Winter 2019

Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments

Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia

Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division

HTA Quarterly | Fall 2018

HTA Quarterly | Late Summer 2018

Connected Health: The Next Healthcare Frontier

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Top Trends in Health Policy in Canada: Insights from InnomarLive

The European Medicines Agency to Find a New Home After Brexit

Are Emerging Value Frameworks a Path to Implementing Value-Based Pricing?

HTA Quarterly | Summer 2018

HTA Quarterly Spring 2018

Achieving Market Access Across the Globe for CGTs

Implementing Coverage With Evidence Development

Recent Trends in Oncology Appraisal Decisions: NICE vs. SMC

Manufacturers

What Do Payers Think About Digital Health Technologies

HTA Quarterly Late Summer 2017

Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options

Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine

HTA Quarterly | Summer 2017

Understanding the Columbian Health Care Market

HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients

Payer Perceptions and Utilization of ICER Value Assessment Framework

HTA Quarterly | Spring 2017

Revisiting the Familiar: Time to Re-evaluate the GVD?

HTA Quarterly | Winter 2017

Indication-specific Pricing: What should manufacturers expect in key markets

HTA Quarterly | Fall 2016

Rapid Access in the US, UK, and France